Captor Therapeutics Spolka Akcyjna (CTX.WA)

Captor Therapeutics Spolka Akcyjna (CTX.WA) — VMCI valuation read

Composite valuation read on CTX.WA: VMCI 38/100 against a Healthcare sector median of 50. The 12-point below-median print is the headline number for Captor Therapeutics Spolka Akcyjna, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for CTX.WA: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on CTX.WA: CTX.WA trades at 17.0x earnings, 6% below the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of -1.7x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

CTX.WA rose 1.4% over the trailing 7 days, with a +5.3% read on a 30-day basis.